LOX and neoplasm: To test if inhibiting LOX could overcome doxorubicin resistance and enhance drug response in advanced, chemotherapy-refractory TNBCs, we re-derived doxorubicin resistance in vivo, using a protocol similar to our initial acquired resistance model (though with lower doxorubicin dose), by treating MDA-MB-231 xenografts with doxorubicin until an accelerated tumor growth was achieved despite the given therapy.